UPST P/E Ratio Analysis
Updated 131h ago·SEC filings & market data
Key Takeaway
The current P/E ratio of 57.1x means investors pay $57.10 for every $1 of the company's trailing earnings, a high price that expects strong future profit growth.
Sector Performance
88th percentileUPST
57.1x
Sector Median
23.1x
Sector Avg
33.8x
Prior Period
69.5x(Jul 2026)
Deep Analysis
The current P/E ratio of 57.1x means investors pay $57.10 for every $1 of the company's trailing earnings, a high price that expects strong future profit growth.
Sector peers trade at a median 23.4x, placing UPST in the 88th percentile among them, so its valuation is far above typical. The metric's year-over-year change is N/A, while quarter-over-quarter it fell 17.7% from 69.5x to 57.1x. Because the level remains elevated despite that quarterly decline, the stock still carries valuation risk rather than a margin of safety. The downward move does offer a modest sign of cooling, but the high percentile keeps the risk level substantial for a non-expert investor. This supports the overall CAUTIOUS verdict, since the high P/E leaves limited room for disappointment in earnings.
Frequently Asked Questions
What does the P/E Ratio tell investors about UPST?
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
How is the P/E Ratio calculated?
P/E Ratio is calculated as: Price / EPS.
Who are UPST's closest peers by P/E Ratio?
The closest peers by P/E Ratio include: CMCSA (7.8x), EG (7.8x), CHRD (7.7x), OXY (7.4x), THC (7.3x).
Learn More About P/E Ratio
The Formula
Price / EPS
Why It Matters
Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.
Master UPST's Valuation
Get the complete institutional research report covering all fundamental and technical metrics.
View full UPST research report →UPST
57.1x
Sector Median
23.1x
Sector Avg
33.8x
How UPST's P/E Ratio compares to sector peers.
Also Analyze
Not financial advice. Research tool only. Data may be delayed.